Table 1.
Characteristics of KRT patients diagnosed with COVID-19, by treatment modality and country
| Dialysis |
Transplant |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All | HD | PD | Austria | French-speaking part of Belgiuma | France | Romania | Spain | Switzerland | The Netherlands | All | France | Spain | |
| No. of patients | 3285 | 3160 | 125 | 44 | 140 | 1631 | 270 | 976 | 87 | 137 | 1013 | 512 | 501 |
| Age at diagnosis, yr, median (IQR) | 71.7 (60.6–80.5) | 71.8 (60.8–80.6) | 70.2 (59.4–78.5) | 71.8 (62.8–81.3) | 71.2 (57.9–78.5) | 72 (60.8–81.2) | 63.2 (52.7–70.2) | 74 (63–81.2) | 73.7 (59.6–81.9) | 73.4 (61–81.5) | 60.9 (51.1–69.4) | 59.6 (49.9–67.9) | 62.5 (52.3–70.9) |
| 0–19 | 9 (0.3) | 8 (0.3) | 1 (0.8) | 0 (0) | NA | 3 (0.2) | 1 (0.4) | 5 (0.5) | 0 (0) | 0 (0) | 8 (0.8) | 4 (0.8) | 4 (0.8) |
| 20–44 | 225 (6.8) | 215 (6.8) | 10 (8.0) | 2 (4.5) | 11 (7.9) | 127 (7.8) | 26 (9.6) | 46 (4.7) | 7 (8.0) | 6 (4.4) | 128 (12.6) | 80 (15.6) | 48 (9.6) |
| 45–64 | 854 (26.0) | 817 (25.9) | 37 (29.6) | 10 (22.7) | 41 (29.3) | 401 (24.6) | 123 (45.6) | 222 (22.7) | 22 (25.3) | 35 (25.5) | 499 (49.3) | 263 (51.4) | 236 (47.1) |
| 65–74 | 857 (26.1) | 823 (26.0) | 34 (27.2) | 15 (34.1) | 34 (24.3) | 429 (26.3) | 82 (30.4) | 245 (25.1) | 16 (18.4) | 36 (26.3) | 260 (25.7) | 115 (22.5) | 145 (28.9) |
| ≥75 | 1340 (40.8) | 1297 (41.0) | 43 (34.4) | 17 (38.6) | 54 (38.6) | 671 (41.1) | 38 (14.1) | 458 (46.9) | 42 (48.3) | 60 (43.8) | 118 (11.6) | 50 (9.8) | 68 (13.6) |
| Sex | |||||||||||||
| Male | 2077 (63.2) | 1993 (63.1) | 84 (67.2) | 24 (54.5) | 97 (69.3) | 1042 (63.9) | 148 (54.8) | 629 (64.4) | 57 (65.5) | 80 (58.4) | 662 (65.4) | 338 (66) | 324 (64.7) |
| Female | 1208 (36.8) | 1167 (36.9) | 41 (32.8) | 20 (45.5) | 43 (30.7) | 589 (36.1) | 122 (45.2) | 347 (35.6) | 30 (34.5) | 57 (41.6) | 351 (34.6) | 174 (34.0) | 177 (35.3) |
| Primary renal disease | |||||||||||||
| Glomerulonephritis | 381 (11.6) | 363 (11.5) | 18 (14.4) | 7 (15.9) | 12 (8.6) | 196 (12.0) | 47 (17.4) | 103 (10.6) | 7 (8.0) | 9 (6.6) | 224 (22.1) | 128 (25.0) | 96 (19.2) |
| Diabetes | 839 (25.5) | 813 (25.7) | 26 (20.8) | 14 (31.8) | 44 (31.4) | 447 (27.4) | 53 (19.6) | 223 (22.8) | 23 (26.4) | 35 (25.5) | 130 (12.8) | 67 (13.1) | 63 (12.6) |
| Hypertension/RVD | 695 (21.2) | 671 (21.2) | 24 (19.2) | 8 (18.2) | 26 (18.6) | 427 (26.2) | 49 (18.1) | 116 (11.9) | 27 (31.0) | 42 (30.7) | 107 (10.6) | 73 (14.3) | 34 (6.8) |
| Other | 1370 (41.7) | 1313 (41.6) | 57 (45.6) | 15 (34.1) | 58 (41.4) | 561 (34.4) | 121 (44.8) | 534 (54.7) | 30 (34.5) | 51 (37.2) | 552 (54.5) | 244 (47.7) | 308 (61.5) |
| Treatment modality | |||||||||||||
| HD | 3160 (96.2) | NA | NA | 43 (97.7) | 133 (95.0) | 1586 (97.2) | 270 (100) | 927 (95.0) | 83 (95.4) | 118 (86.1) | NA | NA | NA |
| PD | 125 (3.8) | NA | NA | 1 (2.3) | 7 (5.0) | 45 (2.8) | 0 (0) | 49 (5.0) | 4 (4.6) | 19 (13.9) | NA | NA | NA |
| Year of KRT start, median (IQR) | 2017 (2014–2018) | 2017 (2013–2018) | 2018 (2017–2019) | 2017 (2013–2019) | 2017 (2014–2019) | 2016 (2013–2018) | 2016 (2012–2019) | 2017b (2015–2019) | 2016 (2013–2018) | 2016 (2014–2018) | 2011 (2005–2016) | 2009 (2003–2014) | 2014b (2007–2017) |
COVID-19, coronavirus disease 2019; HD, hemodialysis; IQR, interquartile range; KRT, kidney replacement therapy; NA, not applicable; PD, peritoneal dialysis; RVD, renovascular disease.
Data are presented as n (%) or median (IQR), unless otherwise specified. Percentages are column percentages. A country was included only if it had >25 dialysis or transplant patients with COVID-19.
a
Data on patients younger than 20 years were not included.
b
Year of starting current treatment modality.